294 related articles for article (PubMed ID: 34681949)
1. EHMT2/G9a as an Epigenetic Target in Pediatric and Adult Brain Tumors.
Souza BK; Freire NH; Jaeger M; de Farias CB; Brunetto AL; Brunetto AT; Roesler R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681949
[TBL] [Abstract][Full Text] [Related]
2. G9a/EHMT2 is a Potential Prognostic Biomarker and Molecular Target in SHH Medulloblastoma.
Souza BK; Freire NH; Jaeger M; de Farias CB; Brunetto AL; Brunetto AT; Roesler R
Neuromolecular Med; 2022 Dec; 24(4):392-398. PubMed ID: 35113321
[TBL] [Abstract][Full Text] [Related]
3. Targeting EHMT2/ G9a for cancer therapy: Progress and perspective.
Jan S; Dar MI; Wani R; Sandey J; Mushtaq I; Lateef S; Syed SH
Eur J Pharmacol; 2021 Feb; 893():173827. PubMed ID: 33347828
[TBL] [Abstract][Full Text] [Related]
4. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
Lu Z; Tian Y; Salwen HR; Chlenski A; Godley LA; Raj JU; Yang Q
Anticancer Drugs; 2013 Jun; 24(5):484-93. PubMed ID: 23466651
[TBL] [Abstract][Full Text] [Related]
5. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
Yokoyama M; Chiba T; Zen Y; Oshima M; Kusakabe Y; Noguchi Y; Yuki K; Koide S; Tara S; Saraya A; Aoyama K; Mimura N; Miyagi S; Inoue M; Wakamatsu T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Yokosuka O; Iwama A
Oncotarget; 2017 Mar; 8(13):21315-21326. PubMed ID: 28423509
[TBL] [Abstract][Full Text] [Related]
6. Histone Methyltransferases G9a/
Souza BK; Freire NH; Monteiro TS; Herlinger AL; Jaeger M; Dalmolin MGS; de Farias CB; Gregianin L; Brunetto AT; Brunetto AL; Thiele CJ; Roesler R
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894922
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J
Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898
[TBL] [Abstract][Full Text] [Related]
8. Nanodiamond-Mediated Delivery of a G9a Inhibitor for Hepatocellular Carcinoma Therapy.
Gu M; Toh TB; Hooi L; Lim JJ; Zhang X; Chow EK
ACS Appl Mater Interfaces; 2019 Dec; 11(49):45427-45441. PubMed ID: 31718136
[TBL] [Abstract][Full Text] [Related]
9. Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
Tao H; Li H; Su Y; Feng D; Wang X; Zhang C; Ma H; Hu Q
Mol Cell Biochem; 2014 Sep; 394(1-2):23-30. PubMed ID: 24833465
[TBL] [Abstract][Full Text] [Related]
10. The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
Mayr C; Helm K; Jakab M; Ritter M; Shrestha R; Makaju R; Wagner A; Pichler M; Beyreis M; Staettner S; Jaeger T; Klieser E; Kiesslich T; Neureiter D
Hum Pathol; 2018 Feb; 72():117-126. PubMed ID: 29133140
[TBL] [Abstract][Full Text] [Related]
11. IVMBIX-01294, an inhibitor of the histone methyltransferase EHMT2, disrupts histone H3 lysine 9 (H3K9) dimethylation in the cleavage-stage porcine embryo.
Park KE; Johnson CM; Cabot RA
Reprod Fertil Dev; 2012; 24(6):813-21. PubMed ID: 22781932
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the G9a/GLP histone methyltransferase complex modulates anxiety-related behavior in mice.
Wang DY; Kosowan J; Samsom J; Leung L; Zhang KL; Li YX; Xiong Y; Jin J; Petronis A; Oh G; Wong AHC
Acta Pharmacol Sin; 2018 May; 39(5):866-874. PubMed ID: 29417943
[TBL] [Abstract][Full Text] [Related]
13. Regulation of
Dobson THW; Hatcher RJ; Swaminathan J; Das CM; Shaik S; Tao RH; Milite C; Castellano S; Taylor PH; Sbardella G; Gopalakrishnan V
Mol Cancer Res; 2017 Aug; 15(8):1073-1084. PubMed ID: 28483947
[TBL] [Abstract][Full Text] [Related]
14. De novo methylation of histone H3K23 by the methyltransferases EHMT1/GLP and EHMT2/G9a.
Vinson DA; Stephens KE; O'Meally RN; Bhat S; Dancy BCR; Cole RN; Yegnasubramanian S; Taverna SD
Epigenetics Chromatin; 2022 Nov; 15(1):36. PubMed ID: 36411491
[TBL] [Abstract][Full Text] [Related]
15. Insights for the design of protein lysine methyltransferase G9a inhibitors.
Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
[TBL] [Abstract][Full Text] [Related]
16. G9a - An Appealing Antineoplastic Target.
Chen WL; Sun HP; Li DD; Wang ZH; You QD; Guo XK
Curr Cancer Drug Targets; 2017; 17(6):555-568. PubMed ID: 27174055
[TBL] [Abstract][Full Text] [Related]
17. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
Li Q; Dong C; Cui J; Wang Y; Hong X
J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
[TBL] [Abstract][Full Text] [Related]
18. Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer.
Thng DKH; Hooi L; Toh CCM; Lim JJ; Rajagopalan D; Syariff IQC; Tan ZM; Rashid MBMA; Zhou L; Kow AWC; Bonney GK; Goh BKP; Kam JH; Jha S; Dan YY; Chow PKH; Toh TB; Chow EK
Mol Oncol; 2023 Nov; 17(11):2275-2294. PubMed ID: 36896891
[TBL] [Abstract][Full Text] [Related]
19. Ethanol induced acetylation of histone at G9a exon1 and G9a-mediated histone H3 dimethylation leads to neurodegeneration in neonatal mice.
Subbanna S; Nagre NN; Shivakumar M; Umapathy NS; Psychoyos D; Basavarajappa BS
Neuroscience; 2014 Jan; 258():422-32. PubMed ID: 24300108
[TBL] [Abstract][Full Text] [Related]
20. The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
Pappano WN; Guo J; He Y; Ferguson D; Jagadeeswaran S; Osterling DJ; Gao W; Spence JK; Pliushchev M; Sweis RF; Buchanan FG; Michaelides MR; Shoemaker AR; Tse C; Chiang GG
PLoS One; 2015; 10(7):e0131716. PubMed ID: 26147105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
